卡铂在三阴性乳腺癌新辅助化疗治疗中的作用
The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.
作者信息
Castrellon Aurelio Bartolome, Pidhorecky Ihor, Valero Vicente, Raez Luis Estuardo
机构信息
Breast Cancer Research, Memorial Cancer Institute, Memorial Healthcare System , Hollywood, FL.
Surgical Oncology Services & Pancreaticobiliary Center, Memorial Cancer Institute, Memorial Healthcare System , Hollywood, FL.
出版信息
Oncol Rev. 2017 Mar 17;11(1):324. doi: 10.4081/oncol.2017.324. eCollection 2017 Mar 3.
Abstract
Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will increase the response rate to preoperative chemotherapy. In this review we present recent studies that have incorporated carboplatin (Cb) in the NACT of TNBC. We discuss the homologous recombination deficiency score and the somatic or germline mutation for BRCA as potential biomarkers for future selection of patients that could benefit from the addition of Cb to NACT.
摘要
三阴性乳腺癌（TNBC）是一组具有组织学和分子差异的异质性疾病。TNBC对新辅助化疗（NACT）的完全病理缓解与预后改善相关。人们一直在努力寻找能提高术前化疗缓解率的联合用药方案。在本综述中，我们介绍了近期将卡铂（Cb）纳入TNBC新辅助化疗的研究。我们讨论了同源重组缺陷评分以及BRCA的体细胞或种系突变，将其作为未来选择可能从在新辅助化疗中添加Cb中获益患者的潜在生物标志物。
相似文献
1
The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.
Oncol Rev. 2017 Mar 17;11(1):324. doi: 10.4081/oncol.2017.324. eCollection 2017 Mar 3.
2
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making.
Cancers (Basel). 2022 Sep 21;14(19):4571. doi: 10.3390/cancers14194571.
3
Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis.
Exp Ther Med. 2022 Jan;23(1):91. doi: 10.3892/etm.2021.11014. Epub 2021 Nov 26.
4
Platinum-based chemotherapy for early triple-negative breast cancer.
Cochrane Database Syst Rev. 2023 Sep 8;9(9):CD014805. doi: 10.1002/14651858.CD014805.pub2.
5
qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
Breast Cancer Res Treat. 2022 Jan;191(2):335-344. doi: 10.1007/s10549-021-06442-x. Epub 2021 Nov 19.
6
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
Ann Oncol. 2021 Dec;32(12):1590-1596. doi: 10.1016/j.annonc.2021.09.003. Epub 2021 Sep 11.
7
Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data.
Ecancermedicalscience. 2021 Feb 1;15:1178. doi: 10.3332/ecancer.2021.1178. eCollection 2021.
8
Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
Breast. 2018 Aug;40:141-146. doi: 10.1016/j.breast.2018.05.007. Epub 2018 May 22.
9
Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial.
Breast Cancer Res Treat. 2023 Nov;202(1):57-65. doi: 10.1007/s10549-023-07011-0. Epub 2023 Aug 14.
10
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Ann Oncol. 2018 Dec 1;29(12):2341-2347. doi: 10.1093/annonc/mdy460.
引用本文的文献
1
Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
J Ovarian Res. 2023 Sep 2;16(1):184. doi: 10.1186/s13048-023-01259-2.
2
Macrophages in immunoregulation and therapeutics.
Signal Transduct Target Ther. 2023 May 22;8(1):207. doi: 10.1038/s41392-023-01452-1.
3
The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial-Mesenchymal Transition.
Int J Mol Sci. 2023 Mar 29;24(7):6422. doi: 10.3390/ijms24076422.
4
Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis.
Clin Exp Med. 2023 Sep;23(5):1489-1499. doi: 10.1007/s10238-022-00894-1. Epub 2022 Sep 24.
5
Carboplatin activates the cGAS-STING pathway by upregulating the TREX-1 (three prime repair exonuclease 1) expression in human melanoma.
Bioengineered. 2021 Dec;12(1):6448-6458. doi: 10.1080/21655979.2021.1972198.
6
Platinum drugs and taxanes: can we overcome resistance?
Cell Death Discov. 2021 Jun 26;7(1):155. doi: 10.1038/s41420-021-00554-5.
7
Update on systemic treatment in early triple negative breast cancer.
Ther Adv Med Oncol. 2021 Jan 31;13:1758835920986749. doi: 10.1177/1758835920986749. eCollection 2021.
8
Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer.
Front Oncol. 2020 Sep 3;10:1658. doi: 10.3389/fonc.2020.01658. eCollection 2020.
9
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
PLoS One. 2020 Aug 25;15(8):e0238021. doi: 10.1371/journal.pone.0238021. eCollection 2020.
10
The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis.
Front Oncol. 2020 Jun 26;10:933. doi: 10.3389/fonc.2020.00933. eCollection 2020.
本文引用的文献
1
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).
NPJ Breast Cancer. 2016;2:15023-. doi: 10.1038/npjbcancer.2015.23. Epub 2016 Jan 6.
2
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
Br J Cancer. 2016 Nov 8;115(10):1157-1173. doi: 10.1038/bjc.2016.311. Epub 2016 Oct 13.
3
Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer.
Breast Cancer (Auckl). 2016 Jul 25;10:103-6. doi: 10.4137/BCBCR.S33163. eCollection 2016.
4
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.
5
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
J Clin Oncol. 2016 Jul 20;34(21):2460-7. doi: 10.1200/JCO.2015.64.8931. Epub 2016 May 2.
6
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.
7
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.
Breast Cancer Res Treat. 2014 Sep;147(2):401-5. doi: 10.1007/s10549-014-3100-x. Epub 2014 Aug 17.
8
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4.
9
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Lancet Oncol. 2014 Jun;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30.
10
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14.
Zotero 插件